Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 4/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.56 |
| ▸ | RELA | Q04206 | 2/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.40 |
| ▸ | PGR | P06401 | 5/20 | 0.40 |
| ▸ | AR | P10275 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15144394 | 0.92 | NFKB1 (0.47) | NFKB1NFKB2RELAKCNH2FNTA | |
| SCHEMBL15147194 | 0.90 | FNTA (0.49) | NFKB1NFKB2RELAKCNH2FNTA | |
| SCHEMBL7565596 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2FNTA | |
| SCHEMBL9619163 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2FNTA | |
| SCHEMBL3083179 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2FNTA | |
| SCHEMBL10419014 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2FNTA | |
| SCHEMBL8207710 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2FNTA | |
| SCHEMBL8192700 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2FNTA | |
| Methyl Alcohol SCHEMBL9756756 | 0.90 | NFKB1 (0.54) | NFKB1NFKB2RELAKCNH2FNTA | |
| SCHEMBL10623020 | 0.89 | ALDH1A1 (0.54) | NFKB1NFKB2RELAKCNH2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145657-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20240307411-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2024-09-19 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220324902-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220324902-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2022-10-13 | — | — | US | disclosed |
| US-20210046089-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210046089-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10799514-B2 | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease | REVERAGEN BIOPHARMA, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20150011519-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. | 2015-01-08 | — | — | US | disclosed |
| EP-2785351-A2 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | Reveragen Biopharma Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20130196962-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | VALIDUS BIOPHARMA, INC (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196962-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | VALIDUS BIOPHARMA, INC (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196962-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | VALIDUS BIOPHARMA, INC (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013082253-A2 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013082253-A2 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | REVERAGEN BIOPHARMA, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| EP-2556083-A2 | NON-HORMONAL STEROID MODULATORS OF NF- KAPPA B FOR TREATMENT OF DISEASE | Validus Biopharma, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011127048-A2 | NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE | VALIDUS BIOPHARMA (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011127048-A2 | NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE | VALIDUS BIOPHARMA (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799514-B2 | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease | NFKBIA, NFKB2, NFKB1 | NFKB1 3/4885NFKB2 2/4885RELA 5/4885 |
| US-20210046089-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NFKB1 3/4885NFKB2 2/4885RELA 5/4885 |
| US-20240307411-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NFKB1 3/4885NFKB2 2/4885RELA 5/4885 |
| US-20150011519-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NFKB1 3/4885NFKB2 2/4885RELA 5/4885 |
| US-20220324902-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NFKB1 3/4885NFKB2 2/4885RELA 5/4885 |
| US-11690853-B2 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | NFKBIA, NFKB2, IKBKG | NFKB1 4/4885NFKB2 2/4885RELA 5/4885 |
| US-20130196962-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NFKB1 3/4885NFKB2 2/4885RELA 12/4885 |
| US-20250145657-A1 | NON-HORMONAL STEROID MODULATORS OF NF-KAPPA BETA FOR TREATMENT OF DISEASE | NFKBIA, NFKB2, NFKB1 | NFKB1 3/4885NFKB2 2/4885RELA 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.